FULL SUPPLEMENT: Time To Get Hands On: Delgocitinib’s Promise For Chronic Hand Eczema

October 2025 | Volume 24 | Issue 10 | 025410 | Copyright © October 2025


Published online September 30, 2025

ET AL

Abstract
Despite its prevalence and impact on patients’ lives, treatment options are limited, with many patients showing inadequate response or intolerance to topical corticosteroids and systemic immunosuppressants. As a result, there is a significant unmet need for effective, well-tolerated, safe nonsteroidal therapies that provide long-term disease control with minimal systemic risk.
In this issue:

VEHICLES MATTER
Chronic hand eczema (CHE), which affects up to 10% of the United States population annually, encompasses a diverse range of presentations. Designation of the condition as "chronic" owes to its persistence or its recurrence...
Read more


The Utility of Delgocitinib in Chronic Hand Eczema

Hand eczema (HE) is a common inflammatory skin condition with a 1-year prevalence of approximately 9 to 10% in the general population and a lifetime prevalence of up to 14.5%.
Read more